What's next for prostate cancer research?

Mae’r cynnwys hwn wedi dod o wefan allanol ac mae ar gael yn Saesneg yn unig.

Prostate cancer is the most common cancer in men, with more than 55,000 newly diagnosed each year in the UK. Men with localised cancer (confined to the prostate) are likely to live for a long time. Based on findings from the landmark National Institute for Health and Care Research (NIHR) trial (ProtecT), national guidelines recommend that men with lower risk localised cancer are offered a choice of: active surveillance (regular monitoring), surgery or radiotherapy. For the future, research is looking for ways to optimise care.

This webinar brings together three large, ongoing NIHR randomised controlled trials involving men with localised cancer. The trials ask whether:

• regular MRI scans improve active surveillance in low to medium risk prostate cancer compared to standard care
• treating only the part of the prostate containing the cancer is as effective as treating the whole prostate, and has fewer side effects, for medium risk cancer
• it is beneficial to remove lymph nodes as well as the prostate in high risk cancer.

This event is being organsied by NIHR, contact the team if you have any queries.